Exploration and Establishment of an Early Warning System for Futile Reperfusion - A I S

June 23, 2025 updated by: Xijing Hospital

FUtile Reperfusion in acuTe iscHEmic stRoke- FURTHER

The goal of this prospective cohort registration study is to establish an early warning system for futile recanalization in acute ischemic stroke by analyzing multi-omics information to identify key regulatory nodes and target molecules in ineffective recanalization.

The core issue addressed by this research is: Identifying key regulatory nodes and target molecules closely associated with futile recanalization, revealing the interactions among the neurovascular unit, peripheral immune cells, and the brain lymphatic system, as well as developing early diagnostic biomarkers and novel diagnostic technologies for futile recanalization.

Study Overview

Status

Enrolling by invitation

Conditions

Study Type

Observational

Enrollment (Estimated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Shanxi
      • Xi'an, Shanxi, China, 710077
        • Luojun WANG

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adults (>18y) with thrombectomy-eligible acute ischemic stroke confirmed by neuroimaging, meeting prespecified inclusion/exclusion criteria

Description

Inclusion Criteria:

  • 1. Aged ≥18 years 2. Acute ischemic stroke confirmed by clinical and neuroimaging criteria (CT or MRI) 3. Clinical indication for thrombectomy 4. Provision of signed informed consent

Exclusion Criteria:

  • 1. Preexisting dementia or severe disability (modified Rankin Scale score ≥3) 2. Cerebral vascular malformations, neoplasms, abscesses, or other significant non-ischemic brain pathologies 3. Life-limiting systemic comorbidities (e.g., end-stage organ failure, metastatic malignancies) with anticipated survival <6 months 4. Patient or legally authorized representative declined consent 5. Anticipated poor protocol adherence or loss to follow-up

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
3-month mRS score
Time Frame: From enrollment to the end of treatment at 3 months
From enrollment to the end of treatment at 3 months

Other Outcome Measures

Outcome Measure
Time Frame
All-cause mortality within 3 months
Time Frame: From enrollment to the end of treatment at 3months
From enrollment to the end of treatment at 3months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Xijing Hospital

Collaborators

National Science and Technology Major Project

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2025

Primary Completion (Estimated)

May 31, 2028

Study Completion (Estimated)

May 31, 2029

Study Registration Dates

First Submitted

June 23, 2025

First Submitted That Met QC Criteria

June 23, 2025

First Posted (Estimated)

July 1, 2025

Study Record Updates

Last Update Posted (Estimated)

July 1, 2025

Last Update Submitted That Met QC Criteria

June 23, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KY20252127

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Ischemic Stroke (AIS)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe